CO5280205A1 - Forma cristalina de eplerenona . - Google Patents

Forma cristalina de eplerenona .

Info

Publication number
CO5280205A1
CO5280205A1 CO00093237A CO00093237A CO5280205A1 CO 5280205 A1 CO5280205 A1 CO 5280205A1 CO 00093237 A CO00093237 A CO 00093237A CO 00093237 A CO00093237 A CO 00093237A CO 5280205 A1 CO5280205 A1 CO 5280205A1
Authority
CO
Colombia
Prior art keywords
eplerenone
crystal form
shaped
mfi
jpeg
Prior art date
Application number
CO00093237A
Other languages
English (en)
Spanish (es)
Inventor
P Barton Kathleen
Thomas B Borchardt
V Carlos Marlon
Desai Sibbash
Leonard J Ferro
Henry T Gaud
Scott Ganser
Clay R Little
S Mudipalli Partha
Mark A Pietz
L Sing Yuen-Lung
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of CO5280205A1 publication Critical patent/CO5280205A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J19/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 by a lactone ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C07J71/0015—Oxiranes at position 9(11)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CO00093237A 1999-12-08 2000-12-06 Forma cristalina de eplerenona . CO5280205A1 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US16960899P 1999-12-08 1999-12-08
US16955699P 1999-12-08 1999-12-08
US16963999P 1999-12-08 1999-12-08
US16980799P 1999-12-08 1999-12-08
US16968399P 1999-12-08 1999-12-08
US16970799P 1999-12-08 1999-12-08

Publications (1)

Publication Number Publication Date
CO5280205A1 true CO5280205A1 (es) 2003-05-30

Family

ID=27558586

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00093237A CO5280205A1 (es) 1999-12-08 2000-12-06 Forma cristalina de eplerenona .

Country Status (18)

Country Link
US (1) US20090149431A1 (https=)
EP (1) EP1175434A2 (https=)
JP (2) JP4219105B2 (https=)
KR (1) KR100584104B1 (https=)
CN (1) CN100413881C (https=)
AR (1) AR074665A2 (https=)
AU (1) AU2041101A (https=)
BR (1) BR0008054A (https=)
CA (1) CA2362845A1 (https=)
CO (1) CO5280205A1 (https=)
EA (1) EA008449B1 (https=)
HU (1) HUP0201457A3 (https=)
IL (2) IL144757A0 (https=)
MY (1) MY143571A (https=)
NO (1) NO20013857L (https=)
NZ (1) NZ513962A (https=)
PE (1) PE20010918A1 (https=)
WO (1) WO2001041535A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20010821A1 (it) * 2001-04-17 2002-10-17 Gienne Pharma S P A Impiego di composti derivati dallo spirolattone per inibire l'azione pro-fibrigenetica delle cellule stellate epatiche e delle cellule musco
US7235655B2 (en) 2002-03-22 2007-06-26 Pharmacia & Upjohn Company Processes to prepare eplerenone
EP2977084B1 (en) 2010-05-10 2017-07-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for the treatment of fluid accumulation in and/ or under the retina
JP6180930B2 (ja) 2010-06-16 2017-08-16 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 創傷治癒過程における再上皮化を刺激するための方法及び組成物
CN104844681B (zh) * 2014-02-13 2016-06-01 合肥久诺医药科技有限公司 一种l晶型依普利酮的精制方法
JP6835836B2 (ja) 2015-10-13 2021-02-24 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 脈絡膜血管新生の処置のための方法及び医薬組成物
EP3490606B8 (en) 2016-07-26 2024-04-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis
CN108059648A (zh) * 2017-12-30 2018-05-22 合肥久诺医药科技有限公司 一种依普利酮溶剂合物及其制备方法
CN113173968A (zh) * 2021-03-19 2021-07-27 江苏康思尔医药科技有限公司 一种依普利酮的纯化方法
US20240366632A1 (en) 2021-08-31 2024-11-07 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of ocular rosacea

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559332A (en) * 1983-04-13 1985-12-17 Ciba Geigy Corporation 20-Spiroxanes and analogues having an open ring E, processes for their manufacture, and pharmaceutical preparations thereof
US4826689A (en) * 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
FR2634376B1 (fr) * 1988-07-21 1992-04-17 Farmalyoc Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation
IT1227626B (it) * 1988-11-28 1991-04-23 Vectorpharma Int Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione
IT1243390B (it) * 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
US5552160A (en) * 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
NZ248813A (en) * 1992-11-25 1995-06-27 Eastman Kodak Co Polymeric grinding media used in grinding pharmaceutical substances
US5346702A (en) * 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5298262A (en) * 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5302401A (en) * 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5340564A (en) * 1992-12-10 1994-08-23 Sterling Winthrop Inc. Formulations comprising olin 10-G to prevent particle aggregation and increase stability
US5336507A (en) * 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5429824A (en) * 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5352459A (en) * 1992-12-16 1994-10-04 Sterling Winthrop Inc. Use of purified surface modifiers to prevent particle aggregation during sterilization
US5587143A (en) * 1994-06-28 1996-12-24 Nanosystems L.L.C. Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5585108A (en) * 1994-12-30 1996-12-17 Nanosystems L.L.C. Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
US5560932A (en) * 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5665331A (en) * 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5662883A (en) * 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5569448A (en) * 1995-01-24 1996-10-29 Nano Systems L.L.C. Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5571536A (en) * 1995-02-06 1996-11-05 Nano Systems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5560931A (en) * 1995-02-14 1996-10-01 Nawosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5503723A (en) * 1995-02-08 1996-04-02 Eastman Kodak Company Isolation of ultra small particles
US5534270A (en) * 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5518738A (en) * 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5622938A (en) * 1995-02-09 1997-04-22 Nano Systems L.L.C. Sugar base surfactant for nanocrystals
US5591456A (en) * 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5573783A (en) * 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5580579A (en) * 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
US5747001A (en) * 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
US5565188A (en) * 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles
US5718919A (en) * 1995-02-24 1998-02-17 Nanosystems L.L.C. Nanoparticles containing the R(-)enantiomer of ibuprofen
WO1998025948A2 (en) * 1996-12-11 1998-06-18 G.D. Searle & Co. Processes for preparation of 9,11-epoxy steroids and intermediates useful therein
EA009176B1 (ru) * 1995-12-11 2007-12-28 Дж.Д.Серл Энд Ко. Способ получения 7-альфа-карбоксил-9,11-эпоксистероидов и промежуточных продуктов, используемых для их получения, и общий способ эпоксидирования по олефиновым двойным связям
DE60005159T2 (de) * 1999-03-05 2004-07-22 G.D. Searle Llc, Chicago Kombinationstherapie von angiotensin-konvertierendem enzym hemmer und epoxy-steroidalem aldosteron antagonist zur behandlung von kardiovaskulären erkrankungen

Also Published As

Publication number Publication date
JP2003515611A (ja) 2003-05-07
AR074665A2 (es) 2011-02-02
CN1433427A (zh) 2003-07-30
US20090149431A1 (en) 2009-06-11
IL144757A (en) 2007-07-24
KR20020003192A (ko) 2002-01-10
JP4219105B2 (ja) 2009-02-04
IL144757A0 (en) 2002-06-30
KR100584104B1 (ko) 2006-05-30
CN100413881C (zh) 2008-08-27
AU2041101A (en) 2001-06-18
EA200100869A1 (ru) 2002-04-25
NO20013857L (no) 2001-10-08
WO2001041535A2 (en) 2001-06-14
HUP0201457A2 (en) 2002-08-28
BR0008054A (pt) 2002-03-12
WO2001041535A3 (en) 2001-11-22
HUP0201457A3 (en) 2003-07-28
EP1175434A2 (en) 2002-01-30
EA008449B1 (ru) 2007-06-29
WO2001041535A9 (en) 2002-07-04
NZ513962A (en) 2004-08-27
MY143571A (en) 2011-05-31
HK1057220A1 (zh) 2004-03-19
CA2362845A1 (en) 2001-06-14
NO20013857D0 (no) 2001-08-08
PE20010918A1 (es) 2001-09-10
JP2007016043A (ja) 2007-01-25

Similar Documents

Publication Publication Date Title
SE9803502D0 (sv) Dimensionsstabila bindemedelssystem
CO5280205A1 (es) Forma cristalina de eplerenona .
AU2001235940A1 (en) Systems and methods for generating and providing previews of electronic files such as web files
PT1193270E (pt) Pirrolobenzodiazepinas
NO974554L (no) FremgangsmÕte for behandling av en underjordisk formasjon
CO5070656A1 (es) Analogos de la rapamicina que contienen tetrazol con perio- dos de vida media mas cortos
FI981132L (fi) Palvelun luvattoman käytön estäminen
NO20000892D0 (no) Enkeltturs perforerings- og gruspakkesystem
ID24320A (id) Turunan-turunan benzopiran tersubstitusi untuk pengobatan radang
ID19781A (id) Dokumen berpengaman
GB9808805D0 (en) Associating files of data
DE60133921D1 (de) Verwendung von rosuvastatin (zd-4522) zur behandlung von heterozygoter familiärer hypercholesterolämie
TR200000338T2 (tr) Polietilen'in hazırlanmasına mahsus bir yöntem.
ID20637A (id) Metode untuk menghambat pembentukan sulfida biogenik
DE69821941D1 (de) Lokalisierung von eingegrabenen leitungen
IT1320219B1 (it) Legante idraulico risultante dalla miscela di un legante solfatico edi un legante comprendente il composto mineralogico c4a3s.
BR9711586A (pt) Compostos e uso dos mesmo
AR007436A1 (es) Cano de forro
CO5261566A1 (es) Compuestos antipicornavirales y composiciones, sus usos farmaceuticos y materiales para su sintesis
DE69432282D1 (de) Mobilfunkgerät und Zusatzgerät, dessen Tasten mit Funktionalität des Mobilfunkgerätes belegt werden können
EP1192561A4 (en) DATABASE MANAGEMENT SYSTEM HAS FINE INDEX AND QUALIFICATION ABILITY
DE69738512D1 (de) Epstein-barr virus type b ctl epitopen
FI19992204L (fi) Luottamuksellisten tietojen välitys
DE69900802D1 (de) MnMgCuZn-Ferrit und dessen Verwendung
NO982603L (no) FremgangsmÕte for brukerinvolvert stansing av ulovlig trÕdl°st samband

Legal Events

Date Code Title Description
FC Application refused